Last reviewed · How we verify
Nifurtimox (Lampit, BAYA2502)
Nifurtimox is a nitrofuran compound that generates reactive oxygen species to kill parasites, particularly effective against Trypanosoma cruzi.
Nifurtimox is a nitrofuran compound that generates reactive oxygen species to kill parasites, particularly effective against Trypanosoma cruzi. Used for Chagas disease (Trypanosoma cruzi infection), Phase 3 investigation for additional parasitic or infectious indications (specific indication not publicly detailed).
At a glance
| Generic name | Nifurtimox (Lampit, BAYA2502) |
|---|---|
| Sponsor | Bayer |
| Drug class | Nitrofuran antiparasitic |
| Target | Parasite DNA and proteins (via reactive oxygen species generation) |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease / Parasitology |
| Phase | Phase 3 |
Mechanism of action
Nifurtimox undergoes metabolic activation to produce free radicals and reactive oxygen species that damage parasite DNA and proteins, leading to cell death. It has been used for decades against Chagas disease and is being investigated in Phase 3 trials for additional indications, potentially including other parasitic or infectious diseases where oxidative stress mechanisms are therapeutically beneficial.
Approved indications
- Chagas disease (Trypanosoma cruzi infection)
- Phase 3 investigation for additional parasitic or infectious indications (specific indication not publicly detailed)
Common side effects
- Peripheral neuropathy
- Gastrointestinal disturbances
- Headache
- Psychosis or psychiatric effects
Key clinical trials
- An Observational Pregnancy Safety Study in Women Who Were Exposed to the Drug Nifurtimox During Pregnancy to Learn About the Risk of Pregnancy Complications and About the Mother's and Baby's Health
- A Study to Learn How Well Nifurtimox Works and How Safe it is in Children Aged 0 to 17 Years With Chagas' Disease, an Inflammatory, Infectious Disease Caused by the Parasite Trypanosoma Cruzi (PHASE3)
- Study on Benefits of Therapy With Nifurtimox in Chagas Disease, a Parasitic Illness Mostly Transmitted to Humans by a Bug, Using Information From Patient Medical Records in Argentina
- Study to Assess the Food Effect on the Pharmacokinetics of Nifurtimox Tablets in Chronic Chagas' Patients - Dietary Habits Study (PHASE1)
- Study to Assess Bioequivalence of a New Nifurtimox Oral Tablet Formulation (PHASE1)
- Study Will Evaluate the Relative Bioavailability, Safety, and Tolerability of Single Doses of Nifurtimox 30 mg Tablets Exhibiting Different in Vitro Dissolution Characteristics, and to Evaluate the Relative Bioavailability of Nifurtimox 30 mg and 120 mg (PHASE1)
- Study to Assess the Food Effect on the Pharmacokinetics of Nifurtimox Tablets in Chronic Chagas' Patients (PHASE1)
- Study to Assess Bioequivalence of 30 and 120 mg Nifurtimox Tablets in Chronic Chagas' Patients (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Nifurtimox (Lampit, BAYA2502) CI brief — competitive landscape report
- Nifurtimox (Lampit, BAYA2502) updates RSS · CI watch RSS
- Bayer portfolio CI